Sharps Technology posts first update on Solana staking income amid SOL price slump

Sharps Technology, a Nasdaq-listed medical device company, provided its first public update on the performance of its Solana (SOL) on-chain yield strategy, revealing that its validator partners have generated approximately 7% gross annualized staking returns before fees. Nearly all of the company's SOL holdings are staked. This disclosure follows Sharps' recent move to become a direct participant in network infrastructure by launching an institutional-grade validator in partnership with Coinbase. Sharps holds just under 2 million SOL, valued near $250 million, making it the fifth-largest publicly traded Solana treasury, though the position is currently underwater as SOL trades near $120, down significantly from its average acquisition cost of $195. The company is employing this staking income strategy as the SOL token price struggles, a trend also seen among other publicly listed Solana treasury holders.

(Source：The Block)